Flow cytometric immunophenotyping for hematologic neoplasms

Blood

Volumn 111, Issue 8, 2008, Pages 3941-3967

  Craig, Fiona E ^a,b   Foon, Kenneth A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD15 ANTIGEN; CD16 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD5 ANTIGEN; CD52 ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD7 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DIPEPTIDYL PEPTIDASE IV; GLYCOPROTEIN P 15095; INTERLEUKIN 2 RECEPTOR ALPHA; MICROSOMAL AMINOPEPTIDASE; PROTEIN KINASE ZAP 70; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; T6 ANTIGEN; UNINDEXED DRUG;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENOTYPE; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPHENOTYPING; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHENOTYPE; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; PROLYMPHOCYTIC LEUKEMIA; REVIEW; BLOOD DISEASE; METHODOLOGY; PATHOLOGY; PLASMA CELL;

FLOW CYTOMETRY; HEMATOLOGIC NEOPLASMS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; IMMUNOPHENOTYPING; PLASMA CELLS;

EID: 43249130717     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-120535     Document Type: Review

References (147)

1. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997;90:2863-2892.
2. Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med. 2006;130:680-90.
3. Jaffe ES, Harris NL, Stein H, W. VJ. Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001.
4. Stetler-Stevenson M, Davis B, Wood B, Braylan R. 2006 Bethesda International Consensus Con ference on Flow Cytometry Immunophenotyping of Hematolymphoid Neoplasia. Cytometry B Clin Cytom. 2007;72B:S3.
5. Davis BH, Holden JT, Bene MC, et al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry B Clin Cytom. 2007;72B:S5-S13.
6. Wood BL, Arroz M, Barnett D, et al. 2006 Bethesda International Consensus recommendations on the immunophneotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom. 2007;72B:S14-S22.
7. Fromm JR, Kussick SJ, Wood BL. Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. Am J Clin Pathol. 2006;126:764-780.
8. Scallon BJ, Snyder LA, Anderson GM, et al. A review of antibody therapeutics and antibody-related technologies for oncology. J Immunother (1997). 2006;29:351-364.
9. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
10. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956-64.
11. Kroft SH. Monoclones, monotypes, and neoplasia pitfalls in lymphoma diagnosis. Am J Clin Pathol. 2004;121:457-459.
12. Attygalle AD, Liu H, Shirali S, et al. Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood. 2004;104:3343-3348.
13. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders [erratum appears in Blood 2001 Jun 1;97: 3678]. Blood. 2001;97:2130-2136.
14. Kussick SJ, Kalnoski M, Braziel RM, Wood BL. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J Clin Pathol. 2004;121:464-472.
15. Li S, Eshleman JR, Borowitz MJ. Lack of surface immunoglobulin light chain expression by flow cytometric immunophenotyping can help diagnose peripheral B-cell lymphoma. Am J Clin Pathol. 2002;118:229-234.
16. Nakase K, Kita K, Shiku H, et al. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms. Am J Clin Pathol. 1996;105:761-768.
17. Shirai T, Hirose S, TO, Nishimura H. CD5+ B cells in autoimmune disease and lymphoid malignancy. Clin Immunol Immunopathol. 1991;59:173-186.
18. Jelic TM, Raj AB, Jin B, Kurczynski EM, Tolaymat N, Chang HH. Expression of CD5 on hematogones in a 7-year-old girl with Shwachman-Diamond syndrome. Pediatr Dev Pathol. 2001;4:505-511.
19. Cook JR, Craig FE, Swerdlow SH. bcl-2 expression by multicolor flow cytometric analysis assists in the diagnosis of follicular lymphoma in lymph node and bone marrow. Am J Clin Pathol. 2003;119:145-151.
20. Hartung L, Bahler DW. Flow cytometric analysis of BCL-2 can distinguish small numbers of acute lymphoblastic leukemia cells from B-cell precursors. Br J Haematol. 2004;127:50-58.
21. Ray S, Craig FE, Swerdlow SH. Abnormal patterns of antigenic expression in follicular lymphoma: a flow cytometric study. Am J Clin Pathol. 2005;124:576-583.
22. Chen W, Asplund SL, McKenna RW, Kroft SH. Characterization of incidentally identified minute clonal B-lymphocyte populations in peripheral blood and bone marrow. Am J Clin Pathol. 2004;122:588-595.
23. Rawstron AC, Green MJ, Kuzmicki A, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood. 2002;100:635-639.
24. Stetler-Stevenson MA, DiGiuseppe JA, Orfao A, et al. Clinical flow cytometric analysis of neoplastic hematolymphoid cells: approved guideline (H43-A2). 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute. 2007;27:1-81.
25. Kennedy GA, Tey S-K, Cobcroft R, et al. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review. Br J Haematol. 2002;119:412-416.
26. Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003;121:287-295.
27. DiRaimondo F, Albitar M, Huh Y, et al. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer. 2002;94:1721-1730.
28. Nelson BP, Variakojis D, Peterson LC. Leukemia phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation. Mod Pathol. 2002;15:1111-1120.
29. Tworek JA, Singleton TP, Schnitzer B, Hsi ED, Ross CW. Flow cytometric and immunohisto-chemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Am J Clin Pathol. 1998;110:582-589.
30. Asplund SL, McKenna RW, Doolittle JE, Kroft SH. CD5-positive B-cell neoplasms of indeterminate immunophenotype: a clinicopathologic analysis of 26 cases. Appl Immunohistochem Mol Morphol. 2005;13:311-317.
31. Meyerson HJ, MacLennan G, Husel W, Tse W, Lazarus HM, Kaplan D. D cyclins in CD5+ B-cell lymphoproliferative disorders. Am J Clin Pathol. 2006;125:241-250.
32. Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL. CD5+ extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol. 1996;105:31-37.
33. Ruiz A, Reischl U, Swerdlow SH, et al. Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter analysis of 34 cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci. Am J Surg Pathol. 2007;31:792-802.
34. Remstein ED, Dogan A, Einerson RR, et al. The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America. Am J Surg Pathol. 2006;30:1546-1553.
35. Lin P, Medeiros LJ. Lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia: an evolving concept. Adv Anat Pathol. 2005;12:246-255.
36. Hunter ZR, Branagan AR, Manning R, et al. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma. 2005;5:246-249.
37. Schop RF, Van Wier SA, Xu R, et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006;169:150-153.
38. Cook JR, Aguilera NI, Reshmi S, et al. Deletion 6q is not a characteristic marker of nodal lym phoplasmacytic lymphoma. Cancer Genet Cytogenet. 2005;162:85-88.
39. Kroft SH, Dawson DB, McKenna RW. Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma: a flow cytometric analysis of seven cases. Am J Clin Pathol. 2001;115:385-395.
40. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99:815-821.
41. Ruchlemer R, Parry-Jones N, Brito-Babapulle V, et al. B-prolymphocytic leukemia with t(11;14) revisited: a splenomegalic form of matle cell lymphoma evolving with leukaemia. Br J Haematol. 2004;125:330-336.
42. Stark AN, Limbert HJ, Roberts BE, Jones RA, Scott CS. Prolymphocytoid transformation of CLL: a clinical and immunological study of 22 cases. Leuk Res. 1986;10:1225-1232.
43. Schlette E, Bueso-Ramos C, Giles F, Glassman A, Hayes K, Medeiros LJ. Mature B-cell leukemias with more than 55% prolymphocytes: a heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol. 2001;115:571-581.
44. Hercher C, Robain M, Davi F, et al. Amulticentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma. 2001;42:981-987.
45. Jasionowski TM, Hartung L, Greenwood JH, Perkins SL, Bahler DW. Analysis of CD10+ hairy cell leukemia. Am J Clin Pathol. 2003;120:228-235.
46. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohisto-chemistry using a tissue microarray. Blood. 2004;103:275-282.
47. McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29:1652-1660.
48. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14; 18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19:25-33.
49. Sharpe RW, Bethel KJ. Hairy cell leukemia: diagnostic pathology. Hematol Oncol Clin North Am. 2006;20:1023-1049.
50. Cessna MH, Hartung L, Tripp S, Perkins SL, Bahler DW. Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol. 2005;123:132-138.
51. Chen Y-H, Tallman MS, Goolsby C, Peterson L. Immunophenotypic variations in hairy cell leukemia. Am J Clin Pathol. 2006;125:251-259.
52. Zaer FS, Braylan RC, Zander DS, Iturraspe JA, Almasri NM. Multiparametric flow cytometry in the diagnosis and characterization of low-grade pulmonary mucosa-associated lymphoid tissue lymphomas. Mod Pathol. 1998;11:525-532.
53. Eshoa C, Perkins S, Kampalath B, Shidham V Juckett M, Chang CC. Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. Am J Clin Pathol. 2001;115:862-867.
54. Xu Y, McKenna RW, Kroft SH. Assessment of CD10 in the diagnosis of small B-cell lymphomas: a multiparameter flow cytometric study. Am J Clin Pathol. 2002;117:291-300.
55. Liu Z, Dong HY, Gorczyca W, et al. CD5- mantle cell lymphoma. Am J Clin Pathol. 2002;118:216-224.
56. Bellido M, Rubiol E, Ubeda J, et al. Flow cytometry using the monoclonal antibody CD10-Pe/Cy5 is a useful tool to identify follicular lymphoma cells. Eur J Haematol. 2001;66:100-106.
57. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846-852.
58. Morice WG, Hodnefield JM, Kurtin PJ, Hanson CA. An unusual case of leukemic mantle cell lymphoma with a blastoid component showing loss of CD5 and aberrant expression of CD10. Am J Clin Pathol. 2004;122:122-127.
59. Dong HY, Gorczyca W, Liu Z, et al. B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol. 2003;119:218-230.
60. Tiesinga JJ, Wu CD, Inghirami G. CD5+ follicle center lymphoma: immunophenotyping detects a unique subset of "floral" follicular lymphoma. Am J Clin Pathol. 2000;114:912-921.
61. Barry TS, Jaffe ES, Kingma DW, et al. CD5+ follicular lymphoma: a clinicopathologic study of three cases. Am J Clin Pathol. 2002;118:589-598.
62. Rassenti LZ, Kipps TJ. Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006;70:209-213.
63. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023-1029.
64. Rassenti LZ, Huynh L,Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
65. Marti G, Orfao A, Goolsby C. ZAP-70 in CLL: towards standardization of a biomarker for patient management: history of clinical cytometry special issue. Cytometry B Clin Cytom. 2006;70:197-200.
66. Marti G, Orfao A, Goolsby CL. ZAP70 editorial: a follow-up to the special issue. Cytometry B Clin Cytom. 2007;72:94-95.
67. Jamal S, Picker LJ, Aquino DB, McKenna RW, Dawson DB, Kroft SH. Immunophenotypic analysis of peripheral T-cell neoplasms: a multiparameter flow cytometric approach. Am J Clin Pathol. 2001;116:512-526.
68. Cady FM, Morice WG. Flow cytometric assessment of T-cell chronic lymphoproliferative disorders. Clin Lab Med. 2007;27:513-532.
69. Hanson CA, Kurtin PJ, Hoyer JD, Katzmann JA. Aberrant T-cell immunophenotype in viral infections: a limitation in the immunophenotypic diagnosis of T-cell lymphoproliferative disorders. Mod Pathol. 1998;11:130A.
70. Morice WG. The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders. Am J Clin Pathol. 2007;127:881-886.
71. Kinney MC, Jones D. Cutaneous T-cell and NK-cell lymphomas: the WHO-EORTC classification and the increasing recognition of specialized tumor types. Am J Clin Pathol. 2007;127:670-686.
72. Alaibac M, Pigozzi B, Belloni-Fortina A, Michelotto A, Saponeri A, Peserico A. CD7 expression in reactive and malignant human skin T-lymphocytes. Anticancer Res. 2003;23:2707-2710.
73. Vonderheid EC, Bigler RD, Kotecha A, et al. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sezary syndrome). J Invest Dermatol. 2001;117:654-662.
74. Lambert C, Genin C. CD3 bright lymphocyte population reveal gammadelta T cells. Cytometry B Clin Cytom. 2004;61:45-53.
75. Dunphy CH, Gardner LJ, Manes JL, Bee CS, Taysi K. CD30+ anaplastic large-cell lymphoma with aberrant expression of CD13: case report and review of the literature. J Clin Lab Anal. 2000;14:299-304.
76. Popnikolov NK, Payne DA, Hudnall SD, et al. CD13-positive anaplastic large cell lymphoma of T-cell origin: a diagnostic and histogenetic problem. Arch Pathol Lab Med. 2000;124:1804-1808.
77. Blakolmer K, Vesely M, Kummer JA, Jurecka W,
78. Mannhalter C, Chott A. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T-(NK/T-) cell lymphomas. Mod Pathol. 2000;13:766-772.
79. Algino KM, Thomason RW, King DE, Montiel MM, Craig FE. CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. Am J Clin Pathol. 1996;106:78-81.
80. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885-892.
81. Foucar K. Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sezary syndrome. Am J Clin Pathol. 2007;127:496-510.
82. Li Y, Braylan R, Al-Quran SZ. Flow-cytometric assessment of T-cell clonality in clinical specimens. LABMEDICINE. 2007;38:477-482.
83. Nowakowski GS, Morice WG, Phyliky RL, Li CY, Tefferi A. Human leucocyte antigen class I and killer immunoglobulin-like receptor expression patterns in T-cell large granular lymphocyte leukaemia. Br J Haematol. 2005;128:490-492.
84. Morice WG, Kurtin PJ, Leibson PJ, Tefferi A, Hanson CA. Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia. Br J Haematol. 2003;120:1026-1036.
85. Vega F, Medeiros LJ, Gaulard P. Hepatosplenic and other gammadelta T-cell lymphomas. Am J Clin Pathol. 2007;127:869-880.
86. Damm-Welk C, Schieferstein J, Schwalm S, Reiter A, Woessmann W. Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: comparison with quantitative polymerase chain reaction. Br J Haematol. 2007;138:459-466.
87. Herling M, Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007;127:687-700.
88. Medeiros LJ, Elenitoba-Johnson KS. Anaplastic large cell lymphoma. Am J Clin Pathol. 2007;127:707-722.
89. Warnke RA, Jones D, Hsi ED. Morphologic and immunophenotypic variants of nodal T-cell lymphomas and T-cell lymphoma mimics. Am J Clin Pathol. 2007;127:511-527.
90. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490-494.
91. Lundell R, Hartung L, Hill S, Perkins SL, Bahler DW. T-cell large granular lymphocyte leukemias have multiple phenotypic abnormalities involving pan-T-cell antigens and receptors for MHC molecules. Am J Clin Pathol. 2005;124:937-946.
92. O'Malley DP. T-cell large granular leukemia and related proliferations. Am J Clin Pathol. 2007;127:850-859.
93. Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8- positive epidermotropic cytotoxic T cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483-492.
94. Han X, Bueso-Ramos CE. Precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma and acute biphenotypic leukemias. Am J Clin Pathol. 2007;127:528-544.
95. Zettl A, deLeeuw R, Haralambieva E, Mueller-Hermelink HK. Enteropathy-type T-cell lymphoma. Am J Clin Pathol. 2007;127:701-706.
96. Hasserjian RP, Harris NL. NK-cell lymphomas and leukemias: a spectrum of tumors with vari able manifestations and immunophenotype. Am J Clin Pathol. 2007;127:860-868.
97. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482-488.
98. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55.
99. Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia. 2005;19:1466-1470.
100. Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia. 2005;19:449-455.
101. Rawstron AC, Owen RG, Davies FE, et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol. 1997;97:46-55.
102. Rawstron A, Barrans S, Blythe D, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol. 1999;104:138-143.
103. Bataille R, Jego G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells: identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica. 2006;91:1234-1240.
104. Smock KJ, Perkins SL, Bahler DW. Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment. Arch Pathol Lab Med. 2007;131:951-955.
105. Kraj M, Poglod R, Kopec-Szlezak J, Sokolowska U, Wozniak J, Kruk B. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma. 2004;45:2281-2289.
106. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients: implications for the differential diagnosis between MGUS and multiple myeloma. Am J Clin Pathol. 1998;152:1655-1665.
107. Sahara N, Takeshita A. Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma. 2004;45:61-65.
108. Pope B, Brown R, Gibson J, Joshua D. The bone marrow plasma cell labeling index by flow cytometry. Cytometry. 1999;38:286-292.
109. Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005;106:2276-2279.
110. Dingli D, Nowakowski GS, Dispenzieri A, et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood. 2006;107:3384-3388.
111. Owen RG, Rawstron AC. Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice. Br J Haematol 2005;128:732-733.
112. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98:2498-2507.
113. Li S, Juco J, Mann KP, Holden JT. Flow cytometry in the differential diagnosis of lymphocyte-rich thymoma from precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Am J Clin Pathol. 2004;121:268-274.
114. Wood BL. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med. 2007;27:551-575.
115. Digiuseppe JA. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy. Clin Lab Med. 2007;27:533-549.
116. Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A. CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol. 2007;128:306-313.
117. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
118. Kussick SJ, Fromm JR, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol. 2005;124:170-181.
119. Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res. 1999;23:615-624.
120. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards awell defined entity? Br J Haematol. 2007;136:539-548.
121. Dunphy CH, Orton SO, Mantell J. Relative contributions of enzyme cytochemistry and flow cytometric immunophenotyping to the evaluation of acute myeloid leukemias with a monocytic component and of flow cytometric immunophenotyping to the evaluation of absolute monocytoses. Am J Clin Pathol. 2004;122:865-874.
122. Krasinskas AM, Wasik MA, Kamoun M, Schret-zenmair R, Moore J, Salhany KE. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation. Am J Clin Pathol. 1998;110:797-805.
123. Kussick SJ, Stirewalt DL, Yi HS, et al. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia. 2004;18:1591-1598.
124. Arber DA. Realistic pathologic classification of acute myeloid leukemias. Am J Clin Pathol. 2001;115:552-560.
125. Borowitz MJ, Hunger SP, Carroll AJ, et al. Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. Blood. 1993;82:1086-1091.
126. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98:979-987.
127. Cherian S, Moore J, Bantly A, et al. Flowcytometric analysis of peripheral blood neutrophils: a simple, objective, independent and potentially clinically useful assay to facilitate the diagnosis of myelodysplastic syndromes. Am J Hematol. 2005;79:243-245.
128. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102:394-403.
129. Maynadie M, Picard F, Husson B, et al. Immunophenotypic clustering of myelodysplastic syndromes. Blood. 2002;100:2349-2356.
130. Xu Y, McKenna RW, Karandikar NJ, Pildain AJ, Kroft SH. Flowcytometric analysis of monocytes as a tool for distinguishing chronic myelomonocytic leukemia from reactive monocytosis. Am J Clin Pathol. 2005;124:799-806.
131. Elghetany MT, Davis BH. Impact of preanalytical variables on granulocytic surface antigen expression: a review. Cytometry B Clin Cytom. 2005;65:1-5.
132. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res. 2007;31:727-736.
133. Escribano L, Garcia Montero AC, Nunez R, Orfao A. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am. 2006;26:535-547.
134. Valent P. Diagnostic evaluation and classification of mastocytosis. Immunol Allergy Clin North Am. 2006;26:515-534.
135. Richards SJ, Barnett D. The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory. Clin Lab Med. 2007;27:577-590.
136. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2003;102:3587-3591.
137. Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181-192.
138. Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559-2265.
139. Donnenberg AD, Donnenberg VS. Rare-event analysis in flow cytometry. Clin Lab Med. 2007;27:627-652.
140. Rawstron AC, de Tute R, Jack AS, Hillmen P. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia. 2006;20:2102-2110.
141. Dworzak MN, Panzer-Grumayer ER. Flow cytometric detection of minimal residual disease in acute lymphoblastic leukemia. Leuk Lymphoma. 2003;44:1445-1455.
142. Vidriales MB, Perez JJ, Lopez-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood. 2003;101:4695-4700.
143. Schultz KR, Pullen DJ, Sather HN, et al. Risk-and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109: 926-935.
144. Venditti A, Maurillo L, Buccisano F, et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia. 2003;17:2178-2182.
145. Sievers EL, Lange BJ, Alonzo TA, et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood. 2003; 101:3398-3406.
146. Nabhan C, Coutre S, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br J Haematol. 2007;136:379-392.
147. Greig B, Oldaker T, Warzynski M, Wood B. Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: recommendations for training and education to perform clinical flow cytometry. Cytometry B Clin Cytom. 2007;72:S23-S33.